A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss

INTRODUCTION: The sodium-glucose cotransporter 2 inhibitor dapagliflozin and the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduce bodyweight via differing and complementary mechanisms. This post hoc analysis investigated the metabolic effects and baseline associations with bodyweigh...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes Ther
Hauptverfasser: Pereira, Maria J., Lundkvist, Per, Kamble, Prasad G., Lau, Joey, Martins, Julian G., Sjöström, C. David, Schnecke, Volker, Walentinsson, Anna, Johnsson, Eva, Eriksson, Jan W.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer Healthcare 2018
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6064580/
https://ncbi.nlm.nih.gov/pubmed/29949016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0449-6
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge